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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) has been shown to be an effective therapy for patients with multiple myeloma 1, 2 . In part, the efficacy of allogeneic HSCT derives from the ability of donor lymphocytes to target both normal and malignant recipient hematopoietic cells and establish full donor chimerism. In instances where recipient myeloma cells persist or relapse after transplant, single infusions of donor lymphocytes without other therapy, can induce partial or complete remissions in approximately 30-40% of patients 3, 4 . Donor T cells are presumed to be the primary effector cells that mediate tumor immunity after allogeneic HSCT 5, 6 but other immunologic mechanisms may also contribute to the elimination of residual tumor cells in this setting. In fact, recent reports have suggested that donor NK cells are also capable of mediating significant tumor immunity after allogeneic HSCT 7 .
Previous studies from our laboratory examined immune reconstitution in patients with myeloma who received T cell depleted HSCT followed by infusion of CD4+ donor lymphocytes 8 . Donor lymphocyte infusions (DLI) induced further tumor responses in all patients with evidence of persistent myeloma and was often associated with the development of normal polyclonal plasma cell infiltrates in the marrow 9, 10 . Concurrent examination of peripheral lymphocytes also demonstrated the polyclonal expansion of donor CD20+ B cells after DLI when compared with similar patients who did not receive DLI 10 . This led us to consider whether B cell responses to myeloma-associated antigens might also contribute to tumor rejection after allogeneic HSCT.
To identify B cell antigens associated with tumor rejection we screened a myeloma cDNA expression library with post-DLI serum from patients who achieved a [11] [12] [13] . From this screening we identified 13 gene products that were reactive with post-DLI serum but negative with pre-BMT and pre-DLI serum 14 . One of the proteins identified in these experiments was B Cell Maturation Antigen (BCMA).
This protein is a member of the TNF receptor superfamily and contains well-defined intracellular, transmembrane and extracellular domains [15] [16] [17] [18] . BCMA, TACI and BAFF-R are three distinct receptors for two ligands, BAFF and APRIL [19] [20] [21] [22] [23] . These two ligands and their associated receptors play important roles in the development of B cell immunity and maintenance of B cell homeostasis 24 . Several recent studies have also documented the expression of BCMA in malignant as well as normal plasma cells and have shown that BAFF signaling through BCMA can result in myeloma cell proliferation in vitro 18, [25] [26] [27] .
Taken together, these studies suggested that BCMA is commonly expressed in myeloma and signaling through BCMA may also contribute to the expansion of myeloma cells in vivo.
To evaluate the significance of antibodies to BCMA in DLI responders we undertook studies to further characterize the specificity of the antibody response as well 
MATERIAL AND METHODS

Patient samples and treatment
Serum samples were obtained after informed consent from normal donors and patients enrolled on clinical trials of allogeneic HSCT. All patients received myeloablative therapy followed by infusion of marrow stem cells from HLA-identical donors. Clinical characteristics of the two DLI responders who developed high titer antibodies against BCMA are summarized in Table 1 . Clinical protocols were approved by the Institutional Review Board of the Dana-Farber/Harvard Cancer Center, and informed consent was obtained from each patient.
BCMA gene expression
BCMA gene expression was measured by high-density oligonucleotide microarrays (U95Av2 Gene Chip, Affymetrix, Santa Clara, CA) using standard methods in a series of primary tumor samples from patients with myeloma and B cell lineage leukemias 14, 28 . Purified CD138 positive plasma cells from normal bone marrow and patients with MGUS were also tested. CEL files were imported into d-Chip BCMA-specific fluorescence for each sample was calculated as the MFI for BCMA-293 minus MFI for vector-293.
Complement-mediated cytotoxicity and ADCC
Specific cell lysis with antibody and complement was measured using a standard 2 hours 51 Cr release assay. Rabbit complement dilutions ranging between 1:2 and 1:40 without additional antibody were tested to determine non-specific complement toxicity and a 1:4 dilution was chosen for all assays. Cells incubated with complement only or For
RESULTS
Expression of BCMA in normal plasma cells and myeloma cells
BCMA is known to be preferentially expressed in mature B cells 15, 17 . Figure 2B , antibodies specific for BCMA were also detected by western blot in patient serum obtained 4 months after DLI. In contrast, pre-BMT and pre-DLI serum samples from the same patient were negative by western blot. These results confirmed that the antibody response post-DLI was specifically directed at epitopes contained in human BCMA protein 14 .
Post-DLI serum is reactive with the cell surface domain of BCMA
BCMA-293 cells were next used to determine whether the antibody response was directed against the extra-cellular domain of BCMA. BCMA-293 cells were incubated with pre-BMT, pre-DLI and post-DLI serum from two patients previously found to be positive when screening the myeloma cDNA library. As shown in Figure 3A , BCMA-293 cells were strongly positive when stained with the anti-BCMA control antibody.
Significant reactivity with BCMA-293 was also found with patient serum obtained after DLI ( Figure 3A ) compared with vector-293 control cells. In contrast, pre-BMT and pre-DLI serum ( Figure 3A ) had no BCMA reactivity compared with vector-293 cells. Serial serum samples obtained before and after DLI from both patients were then tested by flow cytometry. As shown in Figure 3B , antibodies specific for BCMA were first detectable 4 months post-DLI and remained detectable 1.7 years post-DLI in both patients.
Functional effects of anti-BCMA antibodies
Having determined that patients with myeloma who respond to DLI can develop antibody responses directed against the cell surface domain of BCMA we next determined whether these antibodies could mediate lysis of BCMA positive target cells.
As shown in Figure 4A , post-DLI serum from 2 patients was able to initiate complementmediated lysis of BCMA-293 target cells in a dose dependent manner. This lytic effect was specific for BCMA since control vector-293 cells were not affected by the same serum samples.
We also tested the ability of patient serum to mediate ADCC. Testing different E:T ratios ranging from 15:1 to 100:1, the percent lysis increased in a dose dependant manner (data not shown) and a final E:T ratio of 100:1 was used for all subsequent experiments. As shown in Figure 4B , increasing concentrations of post-DLI serum from both patients mediated increased levels of ADCC when tested against BCMA-293 target cells. ADCC activity was also specific for BCMA since control vector-293 cells were not lysed by the same serum samples. The functional activity of patient serum was also tested against primary BCMA positive myeloma cells. As shown in Figure 4C and 4D, post-DLI serum from both patients induced similar levels of ADCC against 2 different BCMA positive allogeneic myeloma cell targets. For comparison, no ADCC was noted when serum from 2 normal donors was tested in the same assay against these primary tumor cells. When tested against 2 primary myeloma samples that did not express cell surface BCMA, post-DLI serum showed no cytotoxicity (data not shown), confirming the specificity of the ADCC response for BCMA. 
Flow cytometric screening for BCMA antibodies
Having established that flow cytometric testing of BCMA-transfectants provided a sensitive method for detecting antibodies specific for BCMA in patient samples, we used this assay to test serum samples from 53 patients with myeloma and other hematologic malignancies who had undergone allogeneic HSCT and 40 normal donors ( Figure 5 ). Using this assay, 4 of 9 myeloma patients who responded to DLI had significant reactivity with BCMA-293. This included 2 patients that had not been positive in previous assays as well as the 2 known positive patients. This difference is likely due to the use of less diluted serum in the flow cytometry assay (1:10 compared to 1:200 or 1:500 dilution). At higher serum concentrations, the sensitivity of the assay was increased and lower levels of BCMA antibodies could be detected in additional DLI responders. As shown in Figure 5 , the mean level of BCMA-specific fluorescence was significantly higher in the 9 myeloma DLI responders compared to 40 normal donors (p=0.000086), 6 myeloma patients who did not respond to DLI (p=0.01), 20 patients with chronic GVHD (p=0.00012), 5 patients with different leukemias who underwent allogeneic HSCT with T cell depleted marrow (p=0.04) and 8 myeloma patients who underwent allogeneic HSCT after non-myeloablative conditioning (p=0.0012). In this latter group, 6 of the 8 patients had persistent disease after transplant and did not respond to treatment. In contrast, BCMA-specific fluorescence was not significantly different in myeloma DLI responders compared to myeloma patients in remission for more than 5 years after allogeneic HSCT with T cell depleted marrow (p=0.30). Interestingly, BCMA-specific fluorescence was also significantly higher in myeloma patients in long-term remission compared to normal donors (p=0.01). Although the presence of BCMA antibodies in this last group of patients
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was not confirmed using other methods, these observations suggest that BCMA antibodies may occur more generally in myeloma patients who maintain long-term remissions after allogeneic HSCT. 32 . As a result, rituximab is commonly used alone or in combination with other agents in the treatment of various B cell lymphomas. Although the primary mechanism of action of rituximab remains controversial, there is strong evidence that both complement activation and ADCC contribute to tumor cell lysis in vivo 33, 34 . In our analysis, antibodies specific for BCMA developed in several DLI responders. Although the derivation of these antibodies was not directly examined, they are presumably derived from donor B cells since these patients also converted to complete donor hematopoiesis after DLI 10 . Like exogenous humanized monoclonal antibodies specific for CD20, these endogenous antibodies specific for BCMA are also able to mediate complement lysis and ADCC of primary myeloma tumor cells and transfectants expressing BCMA surface antigen.
DISCUSSION
Control cells not expressing BCMA were not affected.
Despite the persistence of BCMA antibodies for prolonged periods, neither of the two patients with high titer antibodies developed hypogammaglobulinemia after DLI. Finally, it is important to note that IgG specific for BCMA persisted for over 1 year after DLI in both of our index patients. The present studies have focused on the functional significance of BCMA antibodies that developed in these individuals.
However, the long-term persistence of high-titer IgG antibodies also suggests that this represents a coordinated immune response involving both B and T cell immunity to BCMA. Similar coordinated responses against cell membrane antigens have recently been demonstrated in patients with auto-immune thyroiditis 36 . Further studies will be needed to determine whether BCMA-derived peptides can be presented by MHC molecules and whether BCMA-peptides can also elicit specific T cell responses. If BCMA is found to have also elicited specific T cell immunity in these individuals, this would provide additional support for exploiting BCMA as a new therapeutic target in patients with multiple myeloma. 
